Additionally, IDH mutations have been described in solid tumors such as gliomas, cholangiocarcinoma, chondrosarcoma, and lymphoid malignancies including T cell acute lymphoid leukemia [11–14]. The gene discussed is IDH2; the disease is central nervous system cancer.